|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang
BD and Li LQ: Comparison of survival of patients with BCLC stage a
hepatocellular carcinoma after hepatic resection or transarterial
chemoembolization: A propensity score-based analysis. Ann Surg
Oncol. 21:3069–3076. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li T, Fan J, Qin LX, Zhou J, Sun HC, Qiu
SJ, Ye QH, Wang L and Tang ZY: Risk factors, prognosis and
management of early and late intrahepatic recurrence after
resection of primary clear cell carcinoma of the liver. Ann Surg
Oncol. 18:1955–1963. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arnaoutakis DJ, Mavros MN, Shen F,
Alexandrescu S, Firoozmand A, Popescu I, Weiss M, Wolfgang CL,
Choti MA and Pawlik TM: Recurrence patterns and prognostic factors
in patients with hepatocellular carcinoma in noncirrhotic liver: A
Multi-Institutional analysis. Ann Surg Onco. 21:147–154. 2014.
View Article : Google Scholar
|
|
5
|
Forner A, Llovet J and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhong JH, Ma L, Wu LC, Zhao W, Yuan WP, Wu
FX, Zhang ZM, Huang S, You XM and Li LQ: Adoptive immunotherapy for
postoperative hepatocellular carcinoma: A systematic review. Int J
Clin Pract. 66:21–27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee SC: Prognostic biomarkers for
prediction of recurrence of hepatocellular carcinoma: Current
status and future prospects. World J Gastroenterol. 20:3112–3124.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
You J, Zhuang L, Cheng HY, Yan SM, Yu L,
Huang JH, Tang BZ, Huang ML, Ma YL, Chongsuvivatwong V, et al:
Efficacy of thymosin alpha-1 and interferon alpha in treatment of
chronic viral hepatitis B: A randomized controlled study. World J
Gastroenterol. 12:6715–6721. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim BH, Lee YJ, Kim W, Yoon JH, Jung EU,
Park SJ, Kim YJ and Lee HS: Efficacy of thymosin α-1 plus
peginterferon α-2a combination therapy compared with peginterferon
α-2a monotherapy in HBeAg-positive chronic hepatitis B: A
prospective, multicenter, randomized, open-label study. Scand J
Gastroenterol. 47:1048–1055. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Matteucci C, Minutolo A,
Sinibaldi-Vallebona P, Palamara AT, Rasi G, Mastino A and Garaci E:
Transcription profile of human lymphocytes following in vitro
treatment with thymosin alpha-1. Ann N Y Acad Sci. 1194:6–19. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng SQ, Wu MC, Chen H, Shen F, Yang JH,
Zhao YX and Mo ZW: Influence of thymosin α1 on postoperative
recurrence of primary liver cancer. Chin J Hepatobil Surg.
10:592–593. 2004.(In Chinese).
|
|
12
|
Palmieri G, Biondi E, Morabito A, Rea A
and Bianco A: Could thymostimulin prevent hepatocellular carcinoma
occurrence in patients with liver cirrhosis? Oncol Rep. 3:655–656.
1996.PubMed/NCBI
|
|
13
|
Zhong J, Ke Y, Gong W, Xiang BD, Ma L, Ye
XP, Peng T, Xie GS and Li LQ: Hepatic resection associated with
good survival for selected patients with intermediate and
advanced-stage hepatocellular carcinoma. Ann Surg. 260:329–340.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhong JH, Xiang BD, Gong WF, Ke Y, Mo QG,
Ma L, Liu X and Li LQ: Comparison of long-term survival of patients
with BCLC stage B hepatocellular carcinoma after liver resection or
transarterial chemoembolization. PLoS One. 8:e681932013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Forner A, Reig ME, de Lope CR and Bruix J:
Current strategy for staging and treatment: The BCLC update and
future prospects. Semin Liver Dis. 30:61–74. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chun JM, Kwon HJ, Sohn J, Kim SG, Park JY,
Bae HI, Yun YK and Hwang YJ: Prognostic factors after early
recurrence in patients who underwent curative resection for
hepatocellular carcinoma. J Surg Oncol. 103:148–151. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Poon RT: Differentiating early and late
recurrences after resection of HCC in cirrhotic patients:
Implications on surveillance, prevention, and treatment strategies.
Ann Surg Oncol. 16:792–794. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garaci E, Pica F, Serafino A, Balestrieri
E, Matteucci C, Moroni G, Sorrentino R, Zonfrillo M, Pierimarchi P
and Sinibaldi-Vallebona P: Thymosin α1 and cancer: Action on immune
effector and tumor target cells. Ann N Y Acad Sci. 1269:26–33.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nitta H, Beppu T, Imai K, Hayashi H,
Chikamoto A and Baba H: Adjuvant hepatic arterial infusion
chemotherapy after hepatic resection of hepatocellular carcinoma
with macroscopic vascular invasion. World J Surg. 37:1034–1042.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhong JH, Li H, Li LQ, You XM, Zhang Y,
Zhao YN, Liu JY, Xiang BD and Wu GB: Adjuvant therapy options
following curative treatment of hepatocellular carcinoma: A
systematic review of randomized trials. Eur J Surg Oncol.
38:286–295. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu C, Chen Y, Ho HJ, Hsu YC, Kuo KN, Wu MS
and Lin JT: Association between nucleoside analogues and risk of
hepatitis B virus-related hepatocellular carcinoma recurrence
following liver resection. JAMA. 308:1906–1913. 2012. View Article : Google Scholar : PubMed/NCBI
|
